Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Consensus Rating of “Moderate Buy” from Analysts

Avalyn Pharma Inc. (NASDAQ:AVLN) has been given an average rating of “Moderate Buy” by the seven analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $60.00.

Several equities analysts have recently commented on AVLN shares. Raymond James Financial started coverage on shares of Avalyn Pharma in a report on Friday. They issued an “outperform” rating and a $60.00 target price on the stock. Weiss Ratings assumed coverage on Avalyn Pharma in a research report on Thursday, August 13th. They set a “sell (d+)” rating on the stock. Morgan Stanley increased their price target on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Finally, Wall Street Zen downgraded Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th.

Institutional Investors Weigh In On Avalyn Pharma

Institutional investors have recently made changes to their positions in the company. Montanova Capital LLC bought a new stake in Avalyn Pharma in the second quarter worth about $82,402,000. Bank of New York Mellon Corp purchased a new position in shares of Avalyn Pharma during the second quarter valued at approximately $1,321,000. Braidwell LP bought a new position in shares of Avalyn Pharma during the second quarter valued at approximately $26,382,000. Finally, State Street Corp bought a new position in shares of Avalyn Pharma during the second quarter valued at approximately $10,501,000.

Avalyn Pharma Price Performance

NASDAQ:AVLN opened at $27.03 on Thursday. The stock has a market cap of $1.20 billion and a P/E ratio of -1.19. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. Avalyn Pharma has a 1-year low of $24.15 and a 1-year high of $40.17. The stock has a 50-day simple moving average of $33.48.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.05. Equities analysts anticipate that Avalyn Pharma will post -3.81 EPS for the current fiscal year.

Avalyn Pharma Company Profile

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.